Palbociclib for Breast Cancer Inches Toward FDA ApprovalPalbociclib for Breast Cancer Inches Toward FDA Approval

Palbociclib, the first CDK 4/6 inhibitor, has shown a doubling of progression-free survival in postmenopausal women with ER-positive, HER2-negative advanced-stage breast cancer. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news